Perin, 2012 trial summary

A randomised clinical trial investigating the effect of Bone marrow progenitor cells versus control in patients with advanced ischemic heart failure

Am Heart J 2012;163:415-21, 421.e1  




Studied treatment transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells
Control treatment



Patients patients with advanced ischemic heart failure
Group sizes 10 / 10



Blindness Inclusion period
Follow-up duration 6 months Centers
Lost to FU geographical localisation
Primary endpoint Design



EndpointX1N1X0N0TE95% CI cardiac event - 10 - 10 no data Minnesota Living With Heart Failure Questionnaire - -9 - -9 no data 6-min Walk, m - -9 - -9 no data all-cause mortality - -9 - -9 no data LVEF - -9 - -9 no data acute heart failure - -9 - -9 no data LV End-Systolic Volume - -9 - -9 no data ventricular tachycardia - -9 - -9 no data NT-proBNP - -9 - -9 no data NYHA deterioration - -9 - -9 no data Peak VO2 (mL/kg/min) - -9 - -9 no data NYHA class - -9 - -9 no data0,22,01,0


Perin EC, Silva GV, Zheng Y, Gahremanpour A, Canales J, Patel D, Fernandes MR, Keller LH, Quan X, Coulter SA, Moore WH, Herlihy JP, Willerson JT Randomized, double-blind pilot study of transendocardial injection of autologous aldehyde dehydrogenase-bright stem cells in patients with ischemic heart failure. Am Heart J 2012;163:415-21, 421.e1     [PMID: 22424012]   link to pdf  



Registering number (see trial on clinicaltrials.gov)
Code Name

 




Appears in following systematic reviews: